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Introduction
The most striking and alarming feature in patients
with Guillain-Barre ´ Syndrome (GBS) is progressive
paralysis. Generally, less attention has been paid to
pain, which may be a common and severe symptom
in patients with GBS. Recognition of pain is very
important, especially in patients unable to commu-
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j Abstract Pain can be a serious
problem in patients with Guillain-
Barre ´ syndrome (GBS). Different
pain symptoms and the effect of
methylprednisolone on pain are
evaluated. Methods GBS patients
were recruited from a randomized
placebo-controlled study compar-
ing intravenous immunoglobulin
(IVIg) + methylprednisolone (500
mg for 5 days) versus IVIg + pla-
cebo. Presence and severity of pain
were prospectively scored at ran-
domization and after 4 weeks. Efﬁ-
cacy of methylprednisolone was
evaluated using endpoints: per-
centage of patients with pain and
percentageofpatientsimprovingin
pain-severitylevel.Medicalrecords
of the subgroup of patients treated
in the Erasmus MC were screened
retrospectively for different pain
symptoms and course. Pain was
scored at different time intervals:
within 4 weeks before randomiza-
tion and 0–2, 2–4, 4–24, 24–52
weeks after randomization.
Results 123 (55%) of 223 patients
hadpainatrandomization.In70%,
pain alreadystarted before onset of
weakness. Methylprednisolone did
not show a positive effect on the
presence and reduction of pain. In
the subgroup of 39 patients, back-
ache (33%), interscapular (28%),
muscle(24%),radicularpain(18%)
and painful par-/dysaesthesiae
(18%) were most frequently pres-
ent within the period of 4 weeks
before randomization. Twenty-six
percent had extreme pain 0–2
weeks after randomization. Most
symptoms of pain decreased after
this period, but painful par-/dys-
aesthesiae and muscle pain often
remained present during at least 6
months. Conclusions Pain fre-
quently occurs, often starts before
onset of weakness and may cause
severe complaints. Especially
painful par-/dysaesthesiae and
muscle pain may persist for
months. Methylprednisolone
seems to have no signiﬁcant effect
on the presence and intensity of
pain.
j Key words Guillain-Barre ´
syndrome Æ pain symptoms,
course Æ methylprednisolone
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E-Mail: l.ruts@erasmusmc.nlnicate due to intubation, because treatment against
pain can be offered. Pain as a presenting symptom of
GBS before the onset of weakness may be misleading
in making the diagnosis of GBS and therefore can
cause a delay in starting treatment for GBS.
Pain has been described in 3–89% of patients with
GBS [1, 6, 9, 14]. Different symptoms of pain associ-
ated with GBS have been distinguished: par-/dysaes-
thesiae, backache / root pain, meningism, muscle
pain, joint pain, visceral pain and other types [12].
One larger study in 55 GBS patients subdivided the
different symptoms of pain as reported on admission
into the following: low back pain with radiation
(67.3%), dysaesthetic extremity pain (20%) and
myalgic-rheumatic extremity pain (9.1%) [9]. During
the further non subdivided period of six months,
low back pain with radiation (61.8%), dysaesthet-
ic extremity pain (49.1%) and myalgic-rheumatic
extremity pain (34.5%) were noted [9]. As far as we
know, there are no publications on the more detailed
course and level of severity of the different pain
symptoms during the ﬁrst year after onset of GBS.
Pain in GBS can be very severe, and treatment is
often far from successful. In some cases however a
positive effect of treatment of pain in the acute phase
has been described using corticosteroids [8, 16]. The
pathophysiology of pain is likely multifactorial.
Increased endoneurial ﬂuid pressure in nerve trunks
possessing the epi- and perineurium may play a role
[2]. A possible cause of a salutary effect of corticos-
teroids could be a reduction of the perineurial and
endoneurial inﬂammatory reaction in GBS.
Most reports on the effect of medication to relieve
pain in GBS are based on limited numbers of patients.
When measuring a treatment effect, often all types of
pain are lumped together [4, 8, 10, 11, 15–17]. Because
it is likely that different pathophysiological mecha-
nisms are related to these symptoms, a more detailed
classiﬁcation of different pain symptoms associated
with GBS can be of help to study the effect of drugs.
This study focuses on the frequency, characteris-
tics, severity and course of various symptoms of pain
during the course of GBS and on the effect of
methylprednisolone as was administered in a large
placebo-controlled study.
Methods
j Prospective study
All GBS patients were recruited from a double-blind, randomized
placebo-controlled, multicentre study comparing IVIg + methyl-
prednisolone (500 mg for ﬁve days) versus IVIg + placebo [18]. A
patient was eligible for this trial when the onset of weakness was
within 2 weeks before the date of randomization and the patient
was unable to walk 10 meters across an open space without assis-
tance (GBS disability score ‡ 3). Presence and severity of pain were
collected prospectively at randomization and after 4 weeks. Pain
severity was judged as: none, mild (pain but no real complaints),
moderate (complaints, but no analgesics necessary) or severe
(analgesics necessary).
j Retrospective study
Medical records of the subgroup of GBS patients who entered the
trial and were admitted to the Erasmus MC (the coordinating
center) were retrospectively screened for different pain symptoms.
These symptoms were divided in nine different pain symptoms as
described before [12]. In this subgroup of patients, severity of pain
was judged as: none, severe (analgesics necessary in a way the
complaints were acceptable) or extreme (severe complaints despite
analgesics; deﬁned as feeling uncomfortable due to pain, not well
sleeping due to pain). In the Erasmus MC, treatment of pain in the
acute phase of GBS is standardized following the WHO’s pain
ladder. When a GBS patient after a few weeks suffers from pain
resembling neuropathic pain, we generally start amitriptyline fol-
lowed by anti-convulsants. The different pain syndromes and their
severity were scored at different time-intervals: within 4 weeks
before randomization and 0–2, 2–4, 4–24, 24–52 weeks after ran-
domization. The time points 0 and 4 weeks were ﬁxed visits, during
the other intervals we asked the patient at least once for pain at that
moment and pain since the last visit. Three patients had to be
excluded from the analysis for the time-interval 24–52 weeks after
randomization because of lost to follow-up after 24 weeks.
j Statistics
Percentage of patients with pain and percentage of patients
improving in level of pain-severity in independent groups were
compared by the v
2 test. All calculations were performed using
Stata/SE 8.2 for Windows 2000 (Stata Statistical Software, College
Station, TX 77845, USA). A p-value < 0.05 was considered to be
signiﬁcant.
Results
j Prospective study
225 GBS patients were included in the prospective
study, 2 patients were excluded due to missing data
on the presence of pain. Base-line characteristics,
including the presence of pain at randomization
between the two treatment groups, was not signiﬁ-
cantly different (Table 1). Pain was reported by 123
(55%) of the 223 patients at randomization, 48 (22%)
of these patients had severe pain. Of the 123 patients
with pain, 86 (70%) indicated that the pain preceded
the onset of weakness (median 3 days, range 1 – 36
days). In 84% of the patients starting with pain,
weakness started within one week after the onset of
pain (Figure 1).
4 weeks after randomization, 58 patients (57%) in
the IVIg/placebo group and 51 (49%) in the IVIg/
methylprednisolone group reported pain (no signiﬁ-
cant difference). In individual patients with pain,
there also was no signiﬁcant difference between the
1319IVIg/methylprednisolone and IVIg/placebo group in
decrease or increase of pain severity 4 weeks after
randomization (Table 2).
j Retrospective study
Of the 39 retrospectively analyzed patients, 26 patients
(67%) described one or more symptoms of pain within
the 4 weeks before randomization (Figure 2). 0–2
weeks after randomization, the prevalence rate in-
creased to 79%, where after it decreased. Within the
ﬁrst 2 weeks after randomization, 26% had extreme
pain.
Backache, radicular, interscapular painful par-/
dysaesthesiae and muscle pain most frequently oc-
curred in the beginning of the disease (Table 3). Most
pain symptoms decreased within 2 weeks. However,
painful par-/dysaesthesiae and muscle pain remained
rather constantly present during at least 6 months.
Discussion
In this study, we prospectively investigated the
frequency of pain and the effect of methylpredniso-
lone on pain in a large group of GBS patients included
in a randomized controlled trial. Retrospectively we
investigated the frequency and course of the different
symptoms of pain in more detail in a subgroup
admitted to the coordinating center.
Pain appeared to be highly prevalent in this large,
well documented group of GBS patients. 55% of these
patients had pain at randomization. In other studies,
the incidence of pain during the acute phase varies
between 3% and 86% (median value 50%) [1, 5–7, 9,
13, 14, 19, 20]. This variation mainly seems to be
caused by the rather limited number of patients
included in most studies.
It is remarkable that 70% of the patients reporting
pain at randomization already had this pain prior to
the onset of weakness. Pain as presenting symptom
can lead to diagnostic difﬁculties [3]. When pain
initially is the only symptom, considering GBS as a
possible diagnosis is not always so likely. So pain in
the early phase can be confusing and later on may
cause a delay in diagnosing and starting speciﬁc
treatment for GBS. This is important to realize, be-
cause a delay in diagnosing GBS is potentially life
threatening and may hamper recovery.
In the subgroup of patients that we investigated
retrospectively in more detail, a somewhat higher
percentage of patients (79%) reported pain in the
acute phase compared to the whole group (55%). This
is most likely due to the use of a time-interval of 2
weeks after randomization in stead of the ﬁxed point
in time at randomization.
In the randomized controlled trial, methylpred-
nisolone was primarily evaluated in relation to the
effect on disability of GBS [18]. We did not use a
clinimetrically validated scale to assess the level of
severity of pain. Therefore the results of the effect of
methylprednisolone on pain have to be interpreted
with some caution. In the retrospective part of the
study, we were able to assess the level of pain in more
detail. We did this in relation to the use of analgesics.
Because both treatment of GBS patients and treatment
of pain is standardized in our center, it is likely that
the prescription of analgesics is rather uniform and
reported in a standardized way. This makes it rather
well possible to judge about pain severity at a very
global level in a retrospective way. It appeared that
approximately a quarter of the GBS patients in this
study reported extreme pain in the acute phase indi-
cating that pain is not only a common but also a
severe symptom.
Backache, interscapular and radicular pain were
most frequently present in the acute phase. How-
Table 1 Baseline characteristics of treatment groups at randomization
IVIg/Placebo group
(n = 112)
IVIg/MP group
(n = 111)
Sex distribution (n, (%))
Male 56 (50) 73 (66)
Age (median), years 50 51
F-score (n, (%))
3 32 (29) 26 (23)
4 80 (71) 76 (68)
5 0 (0) 9 (8)
Pain (n, (%))
No 45 (40) 55 (50)
Yes 67 (60) 56 (50)
Mild 24 (21) 17 (15)
Moderate 17 (15) 17 (15)
Severe 26 (23) 22 (20)
MP = methylprednisolone
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Fig. 1 Occurrence of pain before onset of weakness in 86 GBS patients.
Pain = one or more pain symptoms, 86/223 GBS patients started with pain
before onset of weakness
1320ever, painful par-/dysaesthesiae remained rather
constantly present during at least one year (Ta-
ble 3). This trend is comparable to ﬁndings in an-
other larger study in which the different pain
symptoms were noted on admission and during one
further non subdivided period of 24 weeks [9]. The
pathophysiological explanation of pain in GBS is
diverse. It seems that pain in the acute phase is
predominantly nociceptive pain, due to inﬂamma-
tion of the nerve roots and peripheral nerves which
may activate nociceptors. Later on, many GBS pa-
tients have neuropathic pain. This neuropathic pain
is a non-nociceptive pain that doesn’t arise from
pain receptors but results from degeneration and
perhaps even regeneration of nerves and is often
encountered in patients with chronic neuropathies.
The persistence of muscle pain on the other hand
may be related to more mechanical factors due to
limitation of physical activities.
Previous case-reports suggest that corticosteroids
might be an effective treatment for pain, possibly
due to its anti-inﬂammatory effect [8, 16]. This is
the ﬁrst study that evaluated the effect of methyl-
prednisolone on pain in a placebo-controlled way.
We did not ﬁnd a signiﬁcant decrease in the pres-
ence and severity of pain in the methylprednisolone
treated group. This indicates that methylpredniso-
lone for pain in general does not seem to have a
positive effect. However, there are many symptoms
of pain. In previous case reports, corticosteroids
were reported to have a positive effect on radicular
pain. In our series 10 out of 39 patients had
radicular pain. All 5 patients treated with methyl-
prednisolone, but also 4 out of 5 patients treated
with placebo, had a decrease in severity of radicular
pain after 4 weeks. The number of patients with
radicular pain is too small to conclude about a
possible favourable effect of methylprednisolone on
this type of pain in GBS.
In conclusion, pain frequently occurs and may
cause severe complaints in patients with GBS. It often
starts before onset of weakness and therefore can
lead to diagnostic difﬁculties. Most pain symptoms
decrease within 2 weeks, but painful par-/dysaesthe-
siae and muscle pain may persist for months. Meth-
ylprednisolone seems to have no positive effect on the
development and reduction of pain during the acute
phase of GBS.
Table 2 Presence and severity of
pain at randomization and 4 weeks
later
IVIg/Placebo group (n = 112) IVIg/MP group (n = 111)
Patients with pain (n, (%))
Randomization 67 (60) 56 (50)
4 weeks after randomization 58 (57) 51 (49)
Patients with a decrease in pain severity (n, (%))
4 weeks after randomization 34 (34) 32 (31)
Patients with an increase in pain severity (n, (%))
4 weeks after randomization 26 (26) 22 (21)
MP = methylprednisolone
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Fig. 2 Prevalence rate of pain over time in 39 patients with GBS. Pain = one
or more pain symptoms. Extreme pain = severe complaints due to one or more
pain. symptoms despite analgesics; defined as feeling uncomfortable due to
pain, not well sleeping due to pain. Time-interval 24–52: n = 36 patients
Table 3 Prevalence of pain symptoms during course of GBS in 39 patients
Number of weeks related to randomization
Pain symptoms [12] Before After
()4–0) 0–2 2–4 4–24 24–52
*
n (%) n (%) n (%) n (%) n (%)
Backache 13 (33) 11 (28) 1 (3) 2 (5) 0 (0)
Interscapular pain 11 (28) 5 (13) 0 (0) 0 (0) 0 (0)
Muscle pain / cramps 9 (24) 6 (15) 6 (15) 6 (15) 1 (3)
Painful par-/dysaesthesiae 7 (18) 7 (18) 8 (21) 11 (28) 5 (14)
Radicular pain 7 (18) 8 (21) 1 (3) 2 (5) 1 (3)
Others 6 (15) 12 (31) 7 (18) 3 (8) 0 (0)
Joint pain 2 (5) 2 (5) 2 (5) 5 (13) 0 (0)
Visceral pain 2 (5) 4 (10) 4 (10) 3 (8) 0 (0)
Meningism 0 (0) 2 (5) 0 (0) 0 (0) 0 (0)
* n = 36 patients
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